- $8.33bn
- $8.52bn
- $1.16bn
- 91
- 19
- 50
- 53
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 25.57 | ||
| PEG Ratio (f) | 3.2 | ||
| EPS Growth (f) | 8.68% | ||
| Dividend Yield (f) | 0.62% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 4.13 | ||
| Price to Tang. Book | 13.75 | ||
| Price to Free Cashflow | 37.74 | ||
| Price to Sales | 6.89 | ||
| EV to EBITDA | 30.13 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 6.95% | ||
| Return on Equity | 6.53% | ||
| Operating Margin | 14.22% | ||
Financial Summary
| Year End 30th Jun | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 738.69 | 931.03 | 1,105.6 | 1,136.7 | 1,159.06 | 1,217.01 | 1,285.99 | 10.17% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | +97.43 | -35.14 | +81.96 | -11.49 | -11.97 | +46.58 | +8.68 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Directors
- Robert Baumgartner NEC (65)
- Charles Kummeth PRE (61)
- James Hippel CFO (50)
- N. David Eansor CEX (60)
- William Geist CEX (52)
- Kim Kelderman CEX (54)
- Brenda Furlow EVP (63)
- Julie Bushman IND (60)
- John Higgins IND (51)
- Joseph Keegan IND (68)
- Roeland Nusse IND (71)
- Alpna Seth IND (58)
- Randolph Steer IND (71)
- Rupert Vessey IND (56)
- Last Annual
- June 30th, 2024
- Last Interim
- March 31st, 2025
- Incorporated
- July 17th, 1981
- Public Since
- February 9th, 1989
- No. of Shareholders
- 160,000
- No. of Employees
- 3,100
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 156,767,295
- Address
- 614 MCKINLEY PL N E, MINNEAPOLIS, 55413
- Web
- https://www.bio-techne.com/
- Phone
- +1 6123792956
- Contact
- David Clair
- Auditors
- KPMG LLP
Latest News for TECH
Upcoming Events for TECH
Q4 2025 Bio-Techne Corp Earnings Release
Bio-Techne Corp Annual Shareholders Meeting
Q1 2026 Bio-Techne Corp Earnings Release
Similar to TECH
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
Acadia Pharmaceuticals
NASDAQ Global Select Market
FAQ
As of Today at 19:36 UTC, shares in BIO-TECHNE are trading at $53.14. This share price information is delayed by 15 minutes.
Shares in BIO-TECHNE last closed at $53.14 and the price had moved by -25.63% over the past 365 days. In terms of relative price strength the BIO-TECHNE share price has underperformed the S&P500 Index by -33.51% over the past year.
The overall consensus recommendation for BIO-TECHNE is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreThe BIO-TECHNE dividend yield is 0.6% based on the trailing twelve month period.
Last year, BIO-TECHNE paid a total dividend of $0.32, and it currently has a trailing dividend yield of 0.6%. We do not have any data on when BIO-TECHNE is to next pay dividends.
We do not have data on when BIO-TECHNE is to next pay dividends. The historic dividend yield on BIO-TECHNE shares is currently 0.6%.
To buy shares in BIO-TECHNE you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $53.14, shares in BIO-TECHNE had a market capitalisation of $8.33bn.
Here are the trading details for BIO-TECHNE:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: TECH
Based on an overall assessment of its quality, value and momentum BIO-TECHNE is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in BIO-TECHNE is $67.51. That is 27.04% above the last closing price of $53.14.
Analysts covering BIO-TECHNE currently have a consensus Earnings Per Share (EPS) forecast of $1.91 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like BIO-TECHNE. Over the past six months, its share price has underperformed the S&P500 Index by -30.9%.
As of the last closing price of $53.14, shares in BIO-TECHNE were trading -17.55% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The BIO-TECHNE PE ratio based on its reported earnings over the past 12 months is 25.57. The shares last closed at $53.14.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
BIO-TECHNE's management team is headed by:
- Robert Baumgartner - NEC
- Charles Kummeth - PRE
- James Hippel - CFO
- N. David Eansor - CEX
- William Geist - CEX
- Kim Kelderman - CEX
- Brenda Furlow - EVP
- Julie Bushman - IND
- John Higgins - IND
- Joseph Keegan - IND
- Roeland Nusse - IND
- Alpna Seth - IND
- Randolph Steer - IND
- Rupert Vessey - IND